Dr Lalchandani Labs Board of Directors

Get the latest insights into the leadership at Dr Lalchandani Labs. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr. Arjan Lal Chandani Chairman & Managing Director
Mr. Mohit Lal Chandani WholeTime Director & CEO
Mrs. Anchal Gupta Executive Director & CFO
Mrs. Swati Chandra Non Executive Director
Mr. Rajiv Handa Independent Director
Mr. Prakash Jhuraney Independent Director

Dr Lalchandani Labs Share price

DLCL

25.99

0.00 (0.00%)
Last updated on 5 Sep, 2025 | 07:50 IST
BUYSELL
Today's High

00

Today's Low

00

52 Week Low

9.80

52 Week High

28.70

The current prices are delayed, login to your account for live prices

Dr Lalchandani Labs FAQs

The board at Dr Lalchandani Labs consists of experienced professionals, including Dr. Arjan Lal Chandani , Mr. Mohit Lal Chandani , and others, overseeing the company’s strategic and corporate governance.

Directors at Dr Lalchandani Labs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr. Arjan Lal Chandani is the current chairman at Dr Lalchandani Labs.

Executive directors at Dr Lalchandani Labs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Dr Lalchandani Labs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Dr Lalchandani Labs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.